Skip to main content

Table 1 Patient baseline and disease characteristics

From: Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Variable Navoximod 21/28 days BID Navoximod 28/28 days BID All patients (n = 22)
  50 mg (n = 1) 100 mg (n = 3) 200 mg (n = 3) 400 mg (n = 3) 600 mg (n = 3) 800 mg (n = 6) 600 mg (n = 3)  
Age (yr), median (range) 65 (65-65) 58 (50-82) 63 (32-75) 54 (41-69) 58 (27-59) 69 (38-70) 67 (43-72) 61 (27-82)
Sex
 Female 1 (100%) 3 (100%) 3 (100%) 3 (100%) 3 (50%) 2 (67%) 15 (68%)
 Male 3 (100%) 3 (50%) 1 (33%) 7 (32%)
ECOG performance status
 0 1 (100%) 1 (33%) 3 (100%) 1 (33%) 1 (17%) 2 (67%) 9 (41%)
 1 2 (67%) 3 (100%) 2 (67%) 5 (83%) 1 (33%) 13 (59%)
Most common tumor types
 Colorectal 2 (67%) 4 (67%) 6 (27%)
 Head and neck 1 (33%) 1 (33%) 1 (17%) 3 (14%)
 Leiomyosarcoma 1 (33%)   1 (33%) 2 (9%)
 Lung 1 (33%) 1 (33%) 2 (9%)
 Pancreas 1 (33%) 1 (33%) 2 (9%)
 Renal 1 (33%) 1 (17%) 2 (9%)
 Bladder 1 (100%) 1 (5%)
 Breast 1 (33%) 1 (5%)
 Cholangiocarcinoma 1 (33%) 1 (5%)
 Mesothelioma 1 (33%) 1 (5%)
 Testicular 1 (33%) 1 (5%)
Number of prior systemic therapies, median (range)a 5 (5-5) 4 (1-5) 3 (1-3) 4 (3-4) 3 (2-9) 3.5 (2-6)   
  1. ECOG Eastern Cooperative Oncology Group
  2. aAll patients underwent prior systemic therapy